Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company's investigational drug, certepetide, is designed to enhance the targeting and penetration of anti-cancer drugs into solid tumors through a novel uptake pathway [3] Upcoming Presentation - David J. Mazzo, Ph.D., President and CEO of Lisata, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025 [1] - The on-demand recording of Dr. Mazzo's presentation will be available starting September 5, 2025, at 7:00 a.m. Eastern Time [2] Future Expectations - Lisata anticipates announcing numerous milestones over the next 1.5 years and believes its projected capital will fund operations into the fourth quarter of 2026 [3] - The company has established significant commercial and R&D partnerships based on its CendR Platform technology [3]